Literature DB >> 17059999

Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.

Hiromichi Kumagai1, Miyuki Sakurai, Takako Takita, Yukitaka Maruyama, Shuichi Uno, Naoki Ikegaya, Akihiko Kato, Akira Hishida.   

Abstract

BACKGROUND: Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) recently were recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these substances seems to be closely related. This study investigates the association between these substances and whether elevated serum Hcy and ADMA levels are related to high risk for atherosclerosis and cardiovascular events in maintenance hemodialysis (HD) patients.
METHODS: A study was made of 197 HD patients (132 men, 65 women; mean age, 56.9 +/- 8.6 years) for the correlation between plasma total Hcy (tHcy) and ADMA concentrations and the association of these substances with atherosclerotic indices of cervical intima-media thickness, plaque diameter, aortic calcification index, and aortic elongation. Cardiovascular events were followed up for 5 years in these patients.
RESULTS: Mean plasma tHcy (37.3 +/- 25.8 micromol/L) and ADMA (0.77 +/- 0.16 micromol/L) levels were significantly greater in HD patients than in healthy subjects. Plasma tHcy level did not correlate with plasma ADMA level (r = -0.1; P = not significant). Although ADMA level was associated significantly with atherosclerotic indices from a simple regression analysis, this association was less from multiple regression analysis. When patients were classified into 3 groups according to ADMA level, cardiovascular events during 5 years were significantly greater in the group with the highest ADMA levels than in the other groups, confirmed by using a Cox proportional hazard model. However, no association was found between tHcy levels and atherosclerotic indices or cardiovascular events.
CONCLUSION: ADMA level emerged as a potential risk factor for cardiovascular events that might be mediated in part by atherosclerosis in HD patients. Conversely, neither high nor low plasma tHcy levels were associated with atherosclerotic indices and cardiovascular events. This result for our HD patients does not fulfill the terms of traditional epidemiology and paradoxical reverse epidemiology of Hcy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059999     DOI: 10.1053/j.ajkd.2006.08.003

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

Review 1.  Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.

Authors:  Alberto Ortiz; Ziad A Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

2.  Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.

Authors:  Xinli Hu; Dorothee Atzler; Xin Xu; Ping Zhang; Haipeng Guo; Zhongbing Lu; John Fassett; Edzard Schwedhelm; Rainer H Böger; Robert J Bache; Yingjie Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-14       Impact factor: 8.311

Review 3.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

4.  Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.

Authors:  Ping Zhang; Xinli Hu; Xin Xu; Yingjie Chen; Robert J Bache
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-06       Impact factor: 8.311

5.  Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach.

Authors:  Aleksandra M Ignjatović; Tatjana P Cvetković; Radmila M Pavlović; Vidojko M Đorđević; Zoran G Milošević; Vidosava B Đorđević; Dušica D Pavlović; Ivana R Stojanović; Dragan Bogdanović
Journal:  Int Urol Nephrol       Date:  2013-04-17       Impact factor: 2.370

6.  Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplant patients.

Authors:  Aysegul Kudu Cobanoglu; Ozkan Gungor; Fatih Kircelli; Ekrem Altunel; Gulay Asci; Sureyya Suha Ozbek; Huseyin Toz; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2012-12-05       Impact factor: 2.370

Review 7.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

8.  Plasma ADMA predicts restenosis of arteriovenous fistula.

Authors:  Chih-Cheng Wu; Szu-Chi Wen; Chung-Wei Yang; Shih-Yun Pu; Kuei-Chin Tsai; Jaw-Wen Chen
Journal:  J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 10.121

9.  Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine.

Authors:  Xinli Hu; Xin Xu; Guangshuo Zhu; Dorothee Atzler; Masumi Kimoto; Ju Chen; Edzard Schwedhelm; Nicole Lüneburg; Rainer H Böger; Ping Zhang; Yingjie Chen
Journal:  Circulation       Date:  2009-11-16       Impact factor: 29.690

10.  Asymmetric dimethylarginine, race, and mortality in hemodialysis patients.

Authors:  David A Drew; Hocine Tighiouart; Tammy Scott; Amy Kantor; Li Fan; Carlo Artusi; Mario Plebani; Daniel E Weiner; Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.